20 results on '"Oo, H.Z."'
Search Results
2. Proteomic profiling of muscle invasive bladder cancer treated with neoadjuvant chemotherapy
3. 10 - Proteomic profiling of muscle invasive bladder cancer treated with neoadjuvant chemotherapy
4. VAR2-armed CAR T-cells as an immunotherapeutic strategy for bladder cancer
5. Predictive value and potentials for co-targeted therapy of STAT1 signaling in gemcitabine/cisplatin resistant bladder cancer
6. Parallels between immunohistochemical classification of upper and lower tract urothelial carcinoma using markers of urothelial differentiation
7. Independent multicenter validation of the prognostic significance of histopathologic tumor regression grade after neoadjuvant chemotherapy in bladder cancer
8. Biological characterization of cisplatin-resistant bladder cancer: Implications for second-line treatments?
9. Tumor regression grading after neoadjuvant chemotherapy in bladder cancer: Validation in an independent cohort
10. Prognostic impact of immunohistochemical classification of bladder cancer according to luminal (Uroplakin III) and basal (Cytokeratin 5/6) markers
11. 731 - Parallels between immunohistochemical classification of upper and lower tract urothelial carcinoma using markers of urothelial differentiation
12. 479 - Independent multicenter validation of the prognostic significance of histopathologic tumor regression grade after neoadjuvant chemotherapy in bladder cancer
13. 174 - Predictive value and potentials for co-targeted therapy of STAT1 signaling in gemcitabine/cisplatin resistant bladder cancer
14. 1046 Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma
15. 925 STAT1 inhibition restored chemotherapy sensitivity in cisplatin/gemcitabine resistant bladder cancer
16. 791 Notch2-HEY axis promotes tumour growth in bladder cancer through cell cycle progression and de-differentiation
17. 121 TSPAN8 expression in renal cell carcinoma is a poor prognostic factor and a novel therapeutic target
18. 460 - Biological characterization of cisplatin-resistant bladder cancer: Implications for second-line treatments?
19. 387 - Prognostic impact of immunohistochemical classification of bladder cancer according to luminal (Uroplakin III) and basal (Cytokeratin 5/6) markers
20. 390 - Tumor regression grading after neoadjuvant chemotherapy in bladder cancer: Validation in an independent cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.